智能药物递送系统被认为是使用现有非处方药改善癌症治疗的最重要技术之一。然而,金属材料总是伴随着新陈代谢问题,而化疗会在人类中产生一些副作用。碳基材料表现出优异的特征,例如生物亲和力和生物降解性。在这里,据报道,中空介孔碳纳米颗粒(HMC)是抗癌小药物分子的有效纳米载体。近红外(NIR)源,可以穿透大多数器官,通过非侵入性途径诱导热效应。NIR辐射不仅提供热疗,而且与温度敏感的涂覆响应聚合物壳相容。模板法用于合成尺寸为200±50nm的HMC,在各种条件下,以获得用于肝癌治疗的适当尺寸和中空结构。将额外的pH/热双响应聚(N-异丙基丙烯酰胺)(PNIPAM)壳进一步涂覆到HMC上,以产生多个壳,这些壳可以触发PNIPAM@HMC的溶胀运动,如通过小角度X射线散射(SAXS)所证实的。NIR结果表明,HMC和PNIPAM@HMC的ΔT为8.7和14.2°C,分别。使用SasView模拟分析的SAXS光谱证明了合成HMC的多壳结构和PNIPAM@HMC的释放机制。基于SAXS的模型仿真,聚合物溶胀率的不同表明,在37°C和42°C时,核收缩(229.7至134.2µ)和壳膨胀(324.3至514.3µ),分别。此外,一阶,Higuchi,Korsmeyer-Peppas,和Weibull数学模型用于验证药物释放动力学,R2值最高的模型被认为最适合进一步应用。本文首先介绍了SAXS对PNIPAM@HMCs释放动力学和相关机制的研究。这种现象表明NIR诱导的PNIPAM@HMC是通过释放阿霉素治疗癌症的有效策略。
Intelligent drug-delivery systems are considered one of the most important techniques for improving cancer treatment using existing over-the-counter medicines. However, metallic materials are always accompanied by metabolism problems, whereas chemotherapy produces several side effects in humans. Carbon-based materials exhibit exceptional features such as bio-affinity and bio-degradability. Herein, hollow mesoporous carbon nanoparticles (HMCs) are reported as effective nanocarriers of anti-cancer small drug molecules. Near IR (NIR) sources, which can penetrate most organs, induce thermal effects via non-invasive pathways. NIR radiation not only provides thermal therapy but also is compatible with temperature-sensitive coated responsive polymer shells. The template method was used to synthesize HMCs with size 200 ± 50 nm, under various conditions, to obtain suitably sized and hollow structures for liver-cancer treatment. Additional pH/thermal-bi-responsive poly(N-isopropylacrylamide) (PNIPAM) shells were further coated onto the HMCs to produce multiple shells that could trigger swelling motions in PNIPAM@HMCs, as confirmed via small-angle X-ray scattering (SAXS). NIR results demonstrated an extreme increase to the ∆T of 8.7 and 14.2 °C for HMC and PNIPAM@HMCs, respectively. The SAXS spectra analyzed using SasView simulations demonstrated the multi-shell structures of synthesized HMCs and the release mechanism of PNIPAM@HMCs. Based on the model simulation of SAXS, the different rates of polymer swelling indicated the core shrinkage (229.7 to 134.2 Å) and shell expansion (324.3 to 514.3 Å) at 37 °C and 42 °C, respectively. In addition, the first-order, Higuchi, Korsmeyer-Peppas, and Weibull mathematical models were used to verify the drug-release kinetics, and the model with the highest R2 value was considered most suitable for further application. This paper presents the first SAXS study on PNIPAM@HMCs release kinetics and related mechanisms. This phenomenon indicates NIR-induced PNIPAM@HMCs as an effective strategy for cancer treatment via doxorubicin release.